JP2005507648A5 - - Google Patents

Download PDF

Info

Publication number
JP2005507648A5
JP2005507648A5 JP2003514007A JP2003514007A JP2005507648A5 JP 2005507648 A5 JP2005507648 A5 JP 2005507648A5 JP 2003514007 A JP2003514007 A JP 2003514007A JP 2003514007 A JP2003514007 A JP 2003514007A JP 2005507648 A5 JP2005507648 A5 JP 2005507648A5
Authority
JP
Japan
Prior art keywords
polypeptide
compound
nucleic acid
ntb
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003514007A
Other languages
English (en)
Japanese (ja)
Other versions
JP4326944B2 (ja
JP2005507648A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/007945 external-priority patent/WO2003008449A1/en
Publication of JP2005507648A publication Critical patent/JP2005507648A/ja
Publication of JP2005507648A5 publication Critical patent/JP2005507648A5/ja
Application granted granted Critical
Publication of JP4326944B2 publication Critical patent/JP4326944B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003514007A 2001-07-19 2002-07-17 ナチュラルキラー細胞活性に関与する表面分子ntb−a Expired - Fee Related JP4326944B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01401946 2001-07-19
PCT/EP2002/007945 WO2003008449A1 (en) 2001-07-19 2002-07-17 Ntb-a, a surface molecule involved in natural killer cells activity

Publications (3)

Publication Number Publication Date
JP2005507648A JP2005507648A (ja) 2005-03-24
JP2005507648A5 true JP2005507648A5 (enExample) 2006-01-05
JP4326944B2 JP4326944B2 (ja) 2009-09-09

Family

ID=8182813

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003514007A Expired - Fee Related JP4326944B2 (ja) 2001-07-19 2002-07-17 ナチュラルキラー細胞活性に関与する表面分子ntb−a

Country Status (8)

Country Link
US (2) US7138243B2 (enExample)
EP (1) EP1406928B1 (enExample)
JP (1) JP4326944B2 (enExample)
AT (1) ATE464320T1 (enExample)
AU (1) AU2002325333B2 (enExample)
CA (1) CA2454185A1 (enExample)
DE (1) DE60235985D1 (enExample)
WO (1) WO2003008449A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001986A (es) * 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
CN102977213B (zh) 2004-12-28 2017-05-24 依奈特制药公司 抗nkg2a 的单克隆抗体
ES2531933T3 (es) 2006-06-30 2015-03-20 Novo Nordisk A/S Anticuerpos anti-NKG2A y usos de los mismos
WO2008027739A2 (en) * 2006-08-28 2008-03-06 Nuvelo, Inc. Antibodies to ntb-a
US8796427B2 (en) 2008-01-24 2014-08-05 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
WO2012172102A1 (en) 2011-06-17 2012-12-20 Novo Nordisk A/S Selective elimination of erosive cells
EA031025B1 (ru) 2012-12-21 2018-11-30 Сиэтл Дженетикс, Инк. Антитела против ntb-a и связанные с ними композиции и способы
AU2015205327B2 (en) 2014-01-09 2019-02-14 Hadasit Medical Research Services And Development Ltd. Improved cell compositions and methods for cancer therapy
EP3325967B1 (en) 2015-07-24 2019-12-04 Innate Pharma Methods for detecting tissue infiltrating nk cells
WO2019126736A1 (en) * 2017-12-21 2019-06-27 New York University Pd-1 related cancer therapy
WO2019155474A1 (en) 2018-02-12 2019-08-15 Hadasit Medical Research Services & Development Ltd. Modulation of slamf6 splice variants for cancer therapy
CN115461451A (zh) * 2020-06-09 2022-12-09 社会福祉法人三星生命公益财团 用于激活和增幅nk细胞的经基因改造的细胞株以及其用途
CN116179488A (zh) * 2023-03-09 2023-05-30 广东唯泰生物科技有限公司 外周血自然杀伤细胞的体外扩增方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4337197C1 (de) * 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
WO2002024888A2 (en) * 2000-09-01 2002-03-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7425610B2 (en) 2000-01-25 2008-09-16 Nuvelo, Inc. Methods and materials relating to CD84-like polypeptides and polynucleotides
US7029677B2 (en) 2000-01-25 2006-04-18 Nuvelo, Inc. Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
AU2001274888A1 (en) * 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
EP1223218A1 (en) * 2000-11-03 2002-07-17 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules and uses thereof
MXPA03008591A (es) * 2001-03-22 2003-12-08 Bristol Myers Squibb Co Polinucleotido que codifica un miembro de la superfamilia novedosa de inmunoglobulina apex4, variantes y variantes de empalme del mismo.

Similar Documents

Publication Publication Date Title
JP2006515749A5 (enExample)
KR102489353B1 (ko) 특정 집단에 대한 항원으로 t 세포를 스크리닝하기 위한 조성물 및 방법
JP2003501038A5 (enExample)
JP2011509073A5 (enExample)
JP2005504513A5 (enExample)
JP2005507648A5 (enExample)
JP2004512824A5 (enExample)
JP2007297407A5 (enExample)
JP2012115275A5 (enExample)
CA2316280A1 (en) Novel g protein-coupled receptor
JP2017514481A5 (enExample)
JP2009529917A5 (enExample)
JP2004512006A5 (enExample)
WO1995034650A3 (en) Mn gene and protein
CA2443345A1 (en) Disease-associated protein
JP2009513118A5 (enExample)
JP2007526759A5 (enExample)
JP2008502355A5 (enExample)
JP2005511023A5 (enExample)
JPH1066585A5 (enExample)
JP2005535289A5 (enExample)
JP2007508020A5 (enExample)
JP2006502738A5 (enExample)
JP2017525368A5 (enExample)
JP2005516604A5 (enExample)